Familial Nasopharyngeal Carcinoma 6

104 J-C. Lin(Neel et al. 1984a; Neel and Taylor 1990; deVathaire et al. 1988; Yip et al. 1994; Hsu et al. 1988;Twu et al. 2007) and are summarized in Table 9.3. Bythe antibody-dependent cellular cytotoxicity (ADCC)assay, which measures antibodies to an EBV-inducedmembrane antigen component, Neel et al. (1984a)demonstrated that patients with low ADCC titers atdiagnosis had significantly worse progression-freesurvival and overall survival for World HealthOrganization (WHO) Types 2 and 3 NPC patients.Table 9.3. Summary of prognostic impact of serum anti-EBV antibody in nasopharyngeal carcinomaSeries No. Of cases Stage Histology Sampling AssayNeel et al. (1984a) 27I–IVWHO 1Pre-TxADCC107I–IVWHO 2–3Pre-TxADCCNeel and Taylor (1990) 93–WHO 1–3Pre-TxADCC110–WHO 1–3Pre-TxIFMultiple after Txde Vathaire et al. (1988) 373 – – Pre-Tx IF132 – – 1-year after Tx IFYip et al. (1994) 110 I–IV WHO 2–3 Pre-Tx10 m after TxELISAELISAHsu et al. (1988) 179 I–IV WHO 2–3 Multiple IFTwu et al. (2007) 114 II–IV WHO 1–3 Pre-TxIFPost-TxIFPFS progression-free survival; OS overall survival; Tx treatment; ADCC antibody-dependent cellular cytotoxicity; n.s. not statisticallysignificant difference; ncwp No correlation with prognosis; IF indirect immunofluorescence; cwrel correlated withrelapse; ELISA enzyme-linked immunosorbent assay; m month; cwm correlated with distant metastasis; cwrec correlated withlocal recurrence